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Expcrimcnls have dcmonstmled that the cystic fibrosis lransmcmbranc conductance r gulator prolein (CFTR), containing lhe mosl common cystic 
fibrosis (CF)-causing mutation (.4FSOE), reaches lhe plasma membrane inreduced amounts. Studies of a pcptide model of CflR indicate that the 
dF508 mutated region is more sensitive lo dcnaturaling condilions. This paper proposes that altered protein folding accounts for these findings, 
and, thus, most cases of CF. Significantly, the hypothesis makes pecific predictions aboul the effect of stabilizing conditions on mutant CFTR, 
and, further, suggests ::new class of pharmaceuticals that may prove effective in the treatment of this important genetic disease. 
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1. INTRODUCTION 
Cystic fibrosis (CF) is a common fatal autosomal 
recessive disease arising from mutations in the gene 
encoding the cystic fibrosis transmembrane conduct- 
ance regulator (CFTR) protein [1,2]. Although nearly 
200 disease-causing mutations have been identified to 
date, a three base pair deletion, resulting in an in frame 
loss of a phenylalanine residue at position SOS (dF508), 
particularly prevalent in northern European popula- 
tions, accounts for approximately 70% of the disease- 
causing alleles [1,2]. Transfection of several heterolo- 
gous cell types (including cultured airway epithelial 
cells, CFPAC-I, Sf9, HeLa, CHO, NIH 3T3, and Xen- 
opus oocytes) with vectors directing expression of the 
CFTR cDNA result in the appearance of a CAMP- 
dependent chloride conductance in the plasma mem- 
brane [3-,7]. Conversely, expression of the dF508 CFTR 
cDNA in some of these cell types [3,6] did not produce 
this anion conductance, thereby explaining the altered 
chloride conductance of epithelial cells in CF patients 
which underlies the ultimately fatal pulmonary dysfunc- 
tion. Cheng et al. [S] demonstrated that, in COS-7 cells 
expressing the dF508 CFTR, the protein did not reach 
the plasma membrane, and, thus, proposed that defec- 
tive targeting of the mutant protein was responsible for 
the lack of functional expression. Recent studies of a 
synthetic peptide model of the dF508 mutant [9,10] re- 
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veal that defective protein folding may be the molecular 
basis of this aberrant pattern of protein maturation. 
2. DEFECTIVE PROTEIN FOLDING AS THE MO- 
LECULAR BASIS OF CF 
In contrast o earlier esults [3,6], Dalernans et al. [l l] 
and Drumm et al. [ 121 provided evidence that the dF508 
mutant form of CFTR reaches the plasma membrane 
in functional amounts when expressed in fibroblasts 
and oocytes, respectively. However, although the single 
channel anion fluxes of the cells expressing dF508 were 
similar to those for the wild-type, whole- cell measure- 
ments revealed a substantial decrease in anion currents 
[l 1,121. In agreement with the reduced functional activ- 
ity, dF508 CFTR could not be detected at the fibroblast 
cell surface [l 11. Therefore, it appears that, although a 
greatly reduced amount of dF508 CFTR reaches the 
plasma membrane at 37OC in these systems, the fraction 
that is properly processed has the wild-type function. 
These results upport the hypothesis that most cases of 
CF result from defective targeting of the mutant CFTR 
to the apical membrane of epithelial cells [S]. However, 
the molecular basis for the inability of dF508 CFTR to 
reach the membrane remains obscure. 
The basis of the defective localization of mutant 
CFTR may be best explained by dF508 being less stable 
than the wild-type protein, i.e. a temperature-sensitive 
mutant. Improperly folded CFTK would be incapable 
of continuing on the appropriate pathway to the mem- 
brane. Evidence that the moiecuiar basis for the mis- 
processing of dF508 CFTR may be due to destabil- 
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ization have come from studies of synthetic peptides in 
our laboratory 19,101. In agreement with the results of 
Dalemans et al. [I l] and Drumm et al. [12] the mutant 
peptide retained the wild-type nucleotide binding activ- 
ity at 25%. However, the mutant peptide was more 
sensitive to denaturation than was the wild-type, and 
this reduced stability was reflected as reduced nucleo- 
tide binding by the mutant peptide [IO]. Thus, we pro- 
pose that a reduction in stability provides a simple ex- 
planation for the decreased amounts of 4F5OS CFTR 
observed in the membranes of affected cells [3,6,11,12]. 
The fact that the mutant CFTR is functional when it 
reaches the membrane [11,12] can be understood within 
the context of the protein folding hypothesis in two 
ways (Fig. 1). Above we considered the possibility that 
a simple two-state quilibrium between ative and dena- 
tured states is shifted toward the denatured state by the 
4FSOS mutation. Thus, the fact that small but func- 
tional amounts of 4F508 CFTR reach the membrane, 
at least in some cases [I 1,121, would require that condi- 
tions in these cells are near the transition between folded 
and denatured CFTR, that is, where the free energy of 
stabilization is near zero. 
A second possibility is that 4F508 CF is caused by a 
defect in the folding process itself, rather than in de- 
stabilization of the native state. This proposal is illus- 
trated schematically in Fig. 1. Central to this hypothesis 
is the idea that an intermediate in the folding-matura- 
tion pathway is altered by the deletion mutation. The 
mutant intermediate would be potentially more sensi- 
tive to intracellular proteases or to the formation of 
aggregates which would trap CFTR in a form off the 
normal folding pathway, thereby reducing the amount 
of functional, native CFTR in the membrane. In this 
regard, Sturtevant et al. [13] have shown that many 
temperature- sensitive mutants of otherwise stable pro- 
teins are due to thermally labile folding intermediates. 
Furthermore, aggregation of these intermediates may 
be specific [14], perhaps accounting for the homogeneity 
of inclusion bodies formed in bacterial expression sys- 
tems and of plaques formed in amyloid diseases. Fi- 
nally, it is important o note that the peptide model of 
cystic fibrosis [9,10] may be particularly revealing, in the 
sense that synthetic peptides often share characteristics 
with molten globule, or folding intermediate, states, 
such as a significant amount of secondary structure, 
increased conformational entropy, and exposed hydro- 
phobic surfaces. 
3. GLOBAL AND DOMAIN DESTABILIZATION 
The altered protein folding hypothesis o far has con- 
sidered only global destabilization of CFTR. However, 
the peptide results can not distinguish between global 
unfolding of CFTR and unfolding of the N-terminal 
nucleotide binding domain or a portion thereof. While 
the results with CCJS-7 [8], Xenopus oocytes [I?,] and 
8 
i TRANSLATION 1 
WILD AF80B 
l FCICOINU TYPE MUTs+NT 
l MEMBRANE 
TAAQETING INTERMEDIATES 
WILD TYPG CFTR APO01 MUTANT CFTR 
(Normal Amounts) Rxkiced AmhpIts) 
MATURE, FUNCTIONAL CFTR 
Fig. 1. Schematic representation f the maturation of WTR and the 
effect of the dF508 mutation an the process. Maturation of the CFTR 
membrane protein involves three processes: folding of the nascent 
polypeptide chain, glycasylatian, and Iargcting to the appropriate 
membrane location, Protein folding of the denatured polypcpGde into 
a linal nalive structure proceeds through a series of intermediate 
stales. Because ofexposcd hydrophobic surfaces and other non-native 
attributes, ame of obese intermediates may be susceptible ta aggrega- 
tion. Formation of such off-pathway species may prevent appreciable 
amounts of the denatured nascent protein from reaching the native, 
functional structure in the membrane. One can envision that folding 
of the dF508 CFTR to the final ‘native’ structure proceeds through 
a different set of intermediates, some of which may bu kinetically 
trapped, and, therefore, particularly susceptible to aggregation or 
proleolysis. Agents and conditions which prevent formation of the 
aaregatcs or push the folding equilibrium of dF508 CFTR toward 
the native structure may increase the amount of functional protein, 
and, thus, ameliorate the erfects of the CF-causing mutation. 
fibroblasts [l l] indicate that dF508 is a processing mu- 
tant, global destabilization of CFTR may not necessar- 
ily be required. Localized destabilization of the protein 
can not be ruled out, as at least two scenarios might 
explain the observed effects of the deletion mutation. 
First, as has been previously suggested, the sequence 
around F508 may be part of a putative membrane- 
spanning helical domain [15]. If so, the FSOS region may 
be involved in membrane targeting and/or the develop- 
ment of protein topology in the lipid bilayer. Localized 
unfolding could, thus, disrupt a targeting function of 
the region. Secondly, the sequence near F508 has been 
suggested to be involved in inter-domain interactions 
191. It remains possible that these interactions may be 
involved in the maturation of CFTR. 
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4. DISCUSSION 
The evidence that the dFSO8 CFTR is functionally 
active [l 1 ,t2] when it is appropriately processed offers 
new hope for the treatment of CF. Therapies directed 
at correcting the folding defect, in addition to those 
directed at CFTR replacement, can now be envisioned. 
The proposal that dF5OS is a temperature-sensitive 
folding mutant predicts that decreased temperature 
would facilitate appropriate trafficking of the mutant 
protein to the plasma membrane. While lowering a pa- 
tient’s body temperature may not be a treatment of 
choice, perhaps the most intriguing aspect of this pro- 
posal is the potential for new pharmacologies in the 
treatment of cystic fibrosis. Pharmaceuticals that raise 
the permissive temperature by stabilizing dFS0S CFTR 
during the folding process may be suflicient o allow the 
mutant protein to reach the membrane where it can 
perform its biological function. Finally, it has not es- 
caped our attention that other pathological states may 
be caused by similar mechanisms, for example, plaques 
of aggregated protein are formed in amyloid diseases 
such as Alzheimer’s [lG] and familial amyloidotic poly- 
neuropathy [17], as well as in scrapie [IS] and, Z al-anti- 
ttypsin deficiency [19]. In closing, in light of the widc- 
spread occurrence of temperature-sensitive mutants in 
bacterial and yeast systems, perhaps it would not be 
surprising if many human genetic diseases turn out to 
be defects of protein folding. 
[2] Cutting, G.R., Kasch. L.M., Rosenstein, BJ., Ziclcneki, J., Tsui, 
L.-C., Antonarakis, SE. and Kan,tiian, H.H. (1990) Nature 346. 
366-3G9. 
[3] Rich, D.P., Anderson, M.P.. Gregory, R.J.. Chcng, SM., Paul, 
9.. JetTenon. D.M., McCann, J.D,, Klinger, K.W., Smith, A.E. 
and Welsh, M.J. (1990) Nature 347, 358-363. 
141 Drumm, M.L., Pope, H.A., Cliff, W.H.. Rommcns. J.M., 
Marvin, S.A.. Tsui, L.C., Collins, F.S., Frhzell, R.A. and 
Wilson, J.M. (1990) Cell 62, 1227-1233. 
[S] Karthcr, N., Hanrahan, J.W., Jensen, T.J., Naismith. A.L., Sun. 
S., Ackerley, CA., Rcycs, E.F.. Tsui. L.-C., Rommcns, J.M., 
I61 
[71 
181 
Bear, C.E. and Riordan, J.R. (1991) Ccl1 64,681-691. 
Anderson, M.P., Rich, D.P., Gregory, R.J., Smith, A.E. and 
Welsh, M.J. (1991) Science 251, 679-682. 
Bear, C.E., Duguay, F., Naismith, A.L., Kartncr, N.. Hanrahan, 
J.W. and Riordan, J.R. (1991) J. Biol. Chcm. 266, 19142-19145. 
Chcng, S., Gregory, R.J., Marshall, J., Paul, S., SOIIZI, D.W., 
White, G.A., O’Riordan, C.R. and Smith, A.E. (1990) Cell 63. 
827-834. 
A 
[lOI 
[l 11 
1121 
Thomas, P.J., Shenbagamurthi, P..Ysern, X. and Pedersen, P.L. 
(1991) Science 251, 555-557. 
Thomas, P., Shenbaganrurthi, P.. Sondck, J., Hullihcn, J. and 
Pedenen, P.L. (1992) J. Biol. Chem. 267.5727-5730. 
Dalemans, W., Barbry, P., Champ&y, G., Jallat, S., Dott, K., 
Dreyer, D., Crystal, R.G., Pavirani, A., LLmq, J.-P. and Lazdun- 
ski, M. (1991) Nature 354, 52G-528. 
Drumm, M., Wilkinson, D.J.. Smit, L.S., Worrcll, R.T., Strong, 
T.V., Frizzell, R.A., Dawson, DC, and Collins, F.S. (1991) Sci- 
ence 254, 1797-1799. 
[I31 Sturtevant, J.M., Yu, M.-H., Haasc-Pcttingcll, C. dnd King, J. 
(1989) J. Biol. Chem. 264, 10693-IOG98. 
[14] Goldberg, MI.. Rudolph, R. and Jaenicke, R. (1991) Bioehcm- 
islry 30,2790-2797. 
n~~/ro,,~(c~~~/rtrrlrs: This work was supported by NIH Grant 
DK43962 to P.L.P. 
[IS] Shyamala, V., Biachwal, V., Beall, E. and Ames, G.F.-L. (1991) 
J. Biol. Chem. 2G6. 18714-18719. 
[16] Haass. C., Koo, E.H., Mellon, A., Hung, A.Y. and Selkoc, DJ. 
(1992) Nature 357. 500-503. 
REFERENCES 
[I] Riordan, J.K., Rommens, J.M., Kcrem, B-S.. Alon, N., Roz- 
mahel, R., Gnelczak, Z,, Zielcnski, J., Lok, S., Plavsic, N., Chou, 
J.-L., Drumm, M.L., Iannuzzi, MC.. Collins, F.S. and Tsui, 
L.-C, (1989) Science 245, 1066-1073. 
1171 
[I81 
iI91 
Fur&a, I-I., Saraivh, M.J., Gawinowicz, M.A., Alvcs, I.L.,Costa, 
PP., Sasaki, H., Goto, I, and Sakeki, Y. (1991) Biochemistry 30, 
24 Is-242 I * 
Xi, Y.G., Ingrosso, L., Ladogana. A., Masullo, C. and Pocchidri. 
M. (1992) Nature 356,595-601. 
Lomas, D.A., Evans, D.L., Finch, J.T. and Carrell, R.W. (1992) 
Nature 357, 605607. 
Note udded irr proof 
In a report supporting earlier peptide results [lo] and some aspects of the hypothesis presented here, GM. Denning 
et al. [( 1992) Nature 358,761] demonstrated that reduced temperature facilitates the processing of the dF5OS CFTR, 
in 3T3 fibroblasts and Cl27 cells, resulting in the appearance of CAMP-regulated C!- channels in the plasma 
membrane. 
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